Tumor Genomic Profiling in Breast Cancer Patients Using Targeted Massively Parallel Sequencing
Abstract
The overarching goal of this proposal is to use massively parallel sequencing to detect somatic genomic alterations in breast cancer tumor samples in order to identify genetic determinants of tumor behavior that may inform clinical decision-making. We have developed a targeted sequencing platform that interrogates ~450 genes that are known to be altered in breast cancer and other cancers. We now plan to utilize this platform to study 150 tumor samples from women with ER+ breast cancer who have had early-, late- or no relapse following endocrine therapy. We have also sequenced tumor samples from patients with advanced breast cancer. To date, we have obtained metastatic tumor biopsies from 72 patients with ER+ breast cancer and successfully performed whole exome sequencing on 32 patients. Sequencing is being completed on the remaining 40 patients. Analysis of all patients will be conducted once sequencing is complete. In addition, we have performed whole exome sequencing on metastatic tumor biopsies from 65 patients with HER2+ breast cancer. For the subset of these 137 patients who have resistance to targeted therapies, analysis of pre-treatment tumor tissues is currently underway.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 30, 2015
- Accession Number
- ADA621811
Entities
People
- Nikhil Wagle
Organizations
- Dana–Farber Cancer Institute